IN2012DN02982A - - Google Patents

Download PDF

Info

Publication number
IN2012DN02982A
IN2012DN02982A IN2982DEN2012A IN2012DN02982A IN 2012DN02982 A IN2012DN02982 A IN 2012DN02982A IN 2982DEN2012 A IN2982DEN2012 A IN 2982DEN2012A IN 2012DN02982 A IN2012DN02982 A IN 2012DN02982A
Authority
IN
India
Prior art keywords
6alkyl
group
20alkyl
halo
alkyl
Prior art date
Application number
Other languages
English (en)
Inventor
George Kokotos
Berit Johansen
Victoria Magrioti
Michael Tsakos
Original Assignee
Avexxin As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avexxin As filed Critical Avexxin As
Publication of IN2012DN02982A publication Critical patent/IN2012DN02982A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN2982DEN2012 2009-10-02 2010-10-01 IN2012DN02982A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24833809P 2009-10-02 2009-10-02
PCT/EP2010/064687 WO2011039365A1 (fr) 2009-10-02 2010-10-01 2-oxothiazoles et 2-oxooxazoles anti-inflammatoires

Publications (1)

Publication Number Publication Date
IN2012DN02982A true IN2012DN02982A (fr) 2015-07-31

Family

ID=43221889

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2982DEN2012 IN2012DN02982A (fr) 2009-10-02 2010-10-01

Country Status (12)

Country Link
US (2) US9597318B2 (fr)
EP (2) EP2482815B1 (fr)
JP (1) JP6012468B2 (fr)
KR (4) KR20190082985A (fr)
CN (3) CN102647984B (fr)
AU (1) AU2010302584B2 (fr)
CA (1) CA2782797C (fr)
DK (1) DK2482815T3 (fr)
HK (2) HK1197551A1 (fr)
IN (1) IN2012DN02982A (fr)
NO (1) NO2482815T3 (fr)
WO (1) WO2011039365A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2482815T3 (fr) 2009-10-02 2018-09-29
GB201205394D0 (en) 2012-03-27 2012-05-09 Adlens Ltd Improvements in or relating to deformable non-round membrane assemblies
GB201221329D0 (en) 2012-11-27 2013-01-09 Avexxin As Dermatitis treatment
CN110128370A (zh) * 2013-01-29 2019-08-16 埃维克辛公司 抗炎症和抗肿瘤的2-氧代噻唑类和2-氧代噻吩类化合物
GB201307331D0 (en) * 2013-04-23 2013-05-29 Norwegian Univ Sci & Tech Ntnu Compound
GB201409363D0 (en) 2014-05-27 2014-07-09 Avexxin As Skin cancer treatment
GB201413695D0 (en) 2014-08-01 2014-09-17 Avexxin As Compound
GB201604316D0 (en) 2016-03-14 2016-04-27 Avexxin As Combination therapy
GB201604318D0 (en) 2016-03-14 2016-04-27 Avexxin As Combination therapy
GB2550363A (en) * 2016-05-16 2017-11-22 Avexxin As Compound
AU2017329957B2 (en) 2016-09-21 2020-05-07 Avexxin As Pharmaceutical composition
CN109922833A (zh) * 2016-11-04 2019-06-21 埃维克辛公司 治疗皮肤病症的包含噻唑和皮质类固醇的联合治疗
AU2017353450B2 (en) * 2016-11-04 2020-09-10 Avexxin As Combination therapy comprising a thiazole and a secosteroid to treat skin conditions
JP7169584B2 (ja) * 2018-01-30 2022-11-11 公立大学法人横浜市立大学 オーキシン生合成阻害活性を有する新規化合物、その製造方法及びその用途
GB201806663D0 (en) 2018-04-24 2018-06-06 Avexxin As 2-Oxothiazole compositions for treatment of fibrotic disease
EP3677259A1 (fr) * 2019-01-07 2020-07-08 Mosaiques Diagnostics And Therapeutics AG Utilisation d'arachidonyl trifluorométhylcétone
GB202117609D0 (en) 2021-12-06 2022-01-19 Coegin Pharma Ab 2-Oxothiazole compositions for treatment of T-cell acute lymphoblastic leukaemia
CN115028597B (zh) * 2022-04-29 2024-03-26 闽都创新实验室 一种tempo连续脱氢环化制备苯并恶唑类衍生物的方法和应用

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3894152A (en) * 1969-09-15 1975-07-08 Innothera Lab Sa Use of (thienyl-3)(3-N-morpholine-propy)ketone
FR2062868B1 (fr) * 1969-09-15 1973-08-10 Innothera Lab Sa
DE2063901A1 (en) 1970-12-28 1972-07-20 Deutsche Gold- Und Silber-Scheideanstalt Vormals Roessler, 6000 Frankfurt Phenylalkylaminoalkylthiazoles - as antiphlogistics
PH22520A (en) 1984-11-12 1988-10-17 Yamanouchi Pharma Co Ltd Heterocyclic compounds having 4-lover alkyl-3-hydroxy-2-lower alkyl phenoxy-lower alkylene-y-group, and process of producing them
US5177215A (en) 1984-11-12 1993-01-05 Yamanouchi Pharmaceutical Co., Ltd. Heterocyclic compounds and pharmaceutical use thereof
JPS62142168A (ja) 1985-10-16 1987-06-25 Mitsubishi Chem Ind Ltd チアゾ−ル誘導体及びそれを有効成分とするロイコトリエンきつ抗剤
ZA894913B (en) 1988-07-12 1990-03-28 Ici Pharma Heterocyclic compounds
US5272986A (en) 1991-05-13 1993-12-28 British Gas Plc Towing swivel for pipe inspection or other vehicle
TW263504B (fr) 1991-10-03 1995-11-21 Pfizer
GB9211706D0 (en) 1992-06-03 1992-07-15 Celltech Ltd Peptidyl derivatives
US5273986A (en) 1992-07-02 1993-12-28 Hoffmann-La Roche Inc. Cycloalkylthiazoles
US5268395A (en) 1992-10-13 1993-12-07 Martin Marietta Energy Systems, Inc. Microcellular carbon foam and method
JP3345476B2 (ja) * 1993-05-18 2002-11-18 株式会社東芝 有機非線形光学材料
US5569655A (en) * 1993-09-14 1996-10-29 Sterling Winthrop Inc. Substituted heterocyclylisoquinolinium salts and compositions and method of use thereof
WO1996003392A1 (fr) 1994-07-27 1996-02-08 G.D. Searle & Co. Thiazoles substitues destines au traitement de l'inflammation
US6214994B1 (en) * 1997-04-21 2001-04-10 Molecular Geriatrics Corporation Certain substituted 1-aryl-3-piperazin-1′-yl propanones
US5693804A (en) * 1994-11-17 1997-12-02 Molecular Geriatrics Corporation Substituted 1-aryl-3-piperazin-1'-yl propanones
US5658909A (en) * 1994-11-17 1997-08-19 Molecular Geriatrics Corporation Certain substituted 1-aryl-3-piperazin-1'-yl propanones to treat Alzheimer's Disease
TW438786B (en) 1995-03-28 2001-06-07 Nippon Zoki Pharmaceutical Co Novel benzothiazole derivatives
WO1996036617A1 (fr) * 1995-05-19 1996-11-21 G.D. Searle & Co. Oxazoles substitues utilises dans le traitement d'inflammations
CA2224121A1 (fr) * 1995-06-06 1996-12-12 Donna Kaye Wilson Procede stereoselectif de synthese de la dolaphenine
DE19638408A1 (de) * 1996-09-19 1998-03-26 Merckle Gmbh 1-Substituierte 3-Acyl-4,5-dimethylpyrrol-2-carbonsäuren und 3-Acylindol-2-carbonsäuren sowie ihre Derivate als Hemmstoffe der cytosolischen Phospholipase A¶2¶
JP2001509156A (ja) * 1997-01-29 2001-07-10 ゼネカ・リミテッド ファルネシルプロテイントランスフェラーゼの阻害剤
EP0867437B1 (fr) 1997-03-14 2002-11-13 Koninklijke Philips Electronics N.V. Procédé de préparation de composés conjugués contenant le thiophène ou le furanne et composés précurseurs utilisés dans celui-ci
WO1999015129A2 (fr) * 1997-09-23 1999-04-01 Bristol-Myers Squibb Company INHIBITEURS SELECTIFS DE cPLA¿2?
JPH11255700A (ja) 1998-03-12 1999-09-21 Taiho Ind Co Ltd アセチルアセトン系金属錯体及びその合成法、並びにそれを用いた有機多層型エレクトロルミネッセンス素子
KR20010071975A (ko) 1998-08-11 2001-07-31 해슬러 요세 살선충성 피라졸
SE9804212D0 (sv) * 1998-12-04 1998-12-04 Astra Pharma Prod Compounds
EP1196384A4 (fr) 1999-06-25 2002-10-23 Merck & Co Inc 1,3-propanediones-1-(aromatiques ou heteroaromatiques substitutees)-3-(heteroaromatiques substituees) et leur utilisation
JP2001240593A (ja) * 1999-10-12 2001-09-04 Japan Tobacco Inc 高トリグリセリド血症治療薬及び抗肥満薬
US6462054B1 (en) * 2000-03-27 2002-10-08 The Scripps Research Institute Inhibitors of fatty acid amide hydrolase
CN1429224A (zh) 2000-05-18 2003-07-09 第一制药株式会社 新颖苯并噻吩衍生物
US20020052373A1 (en) * 2000-10-26 2002-05-02 Zorn Stevin H. Combination treatment for dementia or cognitive deficits associated with alzheimer's disease and parkinson's disease
US6734207B2 (en) * 2001-04-20 2004-05-11 Parker Hughes Institute Cytotoxic compounds
US7056917B2 (en) 2001-04-26 2006-06-06 Daiichi Pharmaceutical Co., Ltd. Drug efflux pump inhibitor
WO2003051194A1 (fr) 2001-12-18 2003-06-26 3Cpm Company Procede et appareil de mesure endoscopique de l'activite myoelectrique de l'estomac et d'autres organes intra-abdominaux
GB0202002D0 (en) * 2002-01-29 2002-03-13 Leiv Eiriksson Nyotek A S Use
CA2494668A1 (fr) 2002-07-27 2004-02-05 Astrazeneca Ab Composes chimiques
SE0202463D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab Novel compounds
US6930391B2 (en) 2002-08-27 2005-08-16 Intel Corporation Method for alloy-electroplating group IB metals with refractory metals for interconnections
BR0314980A (pt) * 2002-10-08 2005-08-09 Scripps Research Inst Inibidores de hidrolase de amida de ácido graxo
GB2394894B (en) 2002-11-04 2005-08-31 G W Pharma Ltd New use for pharmaceutical composition
AU2003276458A1 (en) 2002-11-07 2004-06-07 Astrazeneca Ab 2-oxo-ethanesulfonamide derivates
JP4663523B2 (ja) 2003-09-18 2011-04-06 株式会社トクヤマ クロメン化合物
SA04250288B1 (ar) * 2003-09-19 2008-07-19 سولفاي فارماسوتيكالز بي . في مشتقات ثيازول thiazole كمعدلات لمستقبل المكونات الكيميائية للقنب cannabinoid
JP4226438B2 (ja) 2003-10-23 2009-02-18 エヌ・ティ・ティ・コムウェア株式会社 パック装置およびセンステーブル装置、ならびに移動軌跡算出方法、移動軌跡算出プログラム、その記録媒体
US20050137243A1 (en) 2003-12-23 2005-06-23 Souers Andrew J. Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor
JP2005343889A (ja) * 2004-05-06 2005-12-15 Taisho Pharmaceut Co Ltd イミダゾピリジン誘導体
CN102816130B (zh) * 2004-05-17 2015-05-06 大塚制药株式会社 噻唑化合物及其用途
US7178364B2 (en) 2004-07-22 2007-02-20 Shapiro Kristen M Personal adornment
WO2006016218A1 (fr) * 2004-08-03 2006-02-16 Pfizer Japan Inc. Dérivés arylcarbonyliques ou hétéroarylcarbonyliques utiles comme antagonistes du récepteur vanilloïde de type 1 (vr1)
WO2006057503A1 (fr) * 2004-11-25 2006-06-01 Lg Life Sciences, Ltd. Nouveaux composes utilises comme agonistes de ppar-gamma et de ppar-alpha, leur procede de preparation, et composition pharmaceutique contenant ces composes
WO2007061862A2 (fr) * 2005-11-18 2007-05-31 Janssen Pharmaceutica N.V. 2-ceto-oxazoles en tant que modulateurs d'amide d'acide gras hydrolase
UA116187C2 (uk) * 2005-12-13 2018-02-26 Інсайт Холдінгс Корпорейшн ГЕТЕРОАРИЛЗАМІЩЕНІ ПІРОЛО[2,3-b]ПІРИДИНИ Й ПІРОЛО[2,3-b]ПІРИМІДИНИ ЯК ІНГІБІТОРИ ЯНУС-КІНАЗИ
CA2642737A1 (fr) 2006-02-17 2007-08-30 The Scripps Research Institute Oxazole-cetones en tant que modulateurs de l'amide d'acide gras hydrolase
WO2008013963A2 (fr) * 2006-07-28 2008-01-31 University Of Connecticut Inhibiteurs d'hydrolase des amides d'acides gras
CA2678735A1 (fr) 2007-02-26 2008-09-04 Santen Pharmaceutical Co., Ltd. Nouveau derive de pyrrole ayant un groupe ureide et un groupe aminocarbonyle comme substituants
MX2009009121A (es) * 2007-03-05 2009-09-03 Hoffmann La Roche Aminoamidas como antagonistas de orexina.
CA2689148A1 (fr) * 2007-05-31 2008-12-11 The Scripps Research Institute Inhibiteurs tricycliques de l'hydrolase amide des acides gras faah
NO2482815T3 (fr) 2009-10-02 2018-09-29
CN103228641A (zh) 2010-11-22 2013-07-31 日立化成株式会社 稀土类金属络合物
CN110128370A (zh) * 2013-01-29 2019-08-16 埃维克辛公司 抗炎症和抗肿瘤的2-氧代噻唑类和2-氧代噻吩类化合物
GB201413695D0 (en) * 2014-08-01 2014-09-17 Avexxin As Compound

Also Published As

Publication number Publication date
EP2482815B1 (fr) 2018-05-02
AU2010302584A1 (en) 2012-05-24
CA2782797A1 (fr) 2011-04-07
US10370344B2 (en) 2019-08-06
KR20120089701A (ko) 2012-08-13
EP3431084A1 (fr) 2019-01-23
CN103772312A (zh) 2014-05-07
KR20190082985A (ko) 2019-07-10
CN102647984B (zh) 2015-03-25
JP6012468B2 (ja) 2016-10-25
CN104892542B (zh) 2018-01-26
CA2782797C (fr) 2018-08-07
CN102647984A (zh) 2012-08-22
KR101997163B1 (ko) 2019-07-08
KR20180114228A (ko) 2018-10-17
KR101907535B1 (ko) 2018-10-15
AU2010302584B2 (en) 2015-09-10
NO2482815T3 (fr) 2018-09-29
HK1210157A1 (en) 2016-04-15
US20170166539A1 (en) 2017-06-15
KR20170038941A (ko) 2017-04-07
CN103772312B (zh) 2016-08-17
EP2482815A1 (fr) 2012-08-08
DK2482815T3 (en) 2018-06-06
WO2011039365A1 (fr) 2011-04-07
US20110136879A1 (en) 2011-06-09
JP2013506639A (ja) 2013-02-28
CN104892542A (zh) 2015-09-09
US9597318B2 (en) 2017-03-21
HK1197551A1 (zh) 2015-01-23

Similar Documents

Publication Publication Date Title
IN2012DN02982A (fr)
AR117799A2 (es) Sal(es) de dimetil-amida del ácido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]-pirimidin-6-carboxílico y procesos para su elaboración
AR116395A2 (es) 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida, su monohidrato o sal en una forma de pureza alta
DK2078026T3 (da) Prodrug-salte af 2, 4-pyrimidinediamine-forbindelser og anvendelser deraf
EA201791584A1 (ru) Агрохимическая композиция
MX351581B (es) Nuevos derivados tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen.
DOP2017000213A (es) Derivados de bencimidazol como inhibidores de bromodominio
NZ599797A (en) Isoxazoline compositions and their use as antiparasitics
EA201790810A1 (ru) Активная композиция для мягчителя ткани
ATE460496T1 (de) Verfahren zur herstellung von l-aminosäure
EA201300282A1 (ru) Производные триазолопиразина
NO20080129L (no) Fremgangsmate for fremstilling av dihydrokinazoliner
NZ701894A (en) Dimethyl-benzoic acid compounds
UA117673C2 (uk) Поліміксини, композиція, спосіб одержання і спосіб застосування (варіанти)
EA201400210A1 (ru) Применение и агрохимическая композиция дибутиламидов карбоновой кислоты
PH12015502429A1 (en) Dicarboxylic acid compound
MX2013011712A (es) Proceso para producir un polimero que contiene vinilamina acilada y su aplicacion como aditivo en la fabricacion de papel.
BR112013030051A2 (pt) método de tratar artigos com dióxido de carbono
MX2016003441A (es) Metodos para producir acidos poliasparticos.
GB201308503D0 (en) Novel microbiocides
TN2014000329A1 (en) Method for preparing compound by novel michael addition reaction using water or various acids as additive
MX2015016665A (es) Composicion dispersante liquida para yeso.
MX2013003581A (es) Proceso para producir granulos que comprende una o mas sales de agentes complejas.
MX2015011743A (es) Un agente quelante de polioxazolina.
BRPI0909752B8 (pt) processos para a produção de sulfonilpirróis como inibidores de hdac e de uma composição farmacêutica compreendendo os mesmos